MarketPulse

orforglipron

6 articles
BenzingaBenzinga··Vandana Singh

Eli Lilly's Oral Weight Loss Drug Clears Cardiovascular Safety Hurdle

Eli Lilly's oral weight loss drug Foundayo met cardiovascular safety goals in Phase 3 trials, showing 57% lower mortality risk versus insulin. FDA filing planned for Q2 2026.
LLYFDA approvalweight-loss drug
The Motley FoolThe Motley Fool··Justin Pope

Eli Lilly's FDA-Approved Obesity Pill Could Upend Novo Nordisk's Market Dominance

Eli Lilly's new GLP-1 pill Foundayo launches April 6 with fewer restrictions than competitors. Pipeline drug retatrutide shows superior weight loss, threatening Novo Nordisk's obesity market leadership.
LLYNVOFDA approvalGLP-1 drugs
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly's April 10 FDA Decision Could Transform Weight Loss Market, But Patience Pays

Eli Lilly awaits April 10 FDA decision on oral weight loss drug orforglipron, amid $11B quarterly sales from current portfolio. Approval could catalyze gains, but long-term fundamentals matter more than short-term decisions.
LLYNVOFDA approvalGLP-1 drugs
BenzingaBenzinga··Vandana Singh

HSBC Slashes Eli Lilly Price Target, Warns Obesity Drug Market Vastly Overhyped

HSBC downgraded $LLY to Reduce, citing inflated obesity market projections. The analyst sees $80-120B market by 2032, not Wall Street's $150B estimate.
LLYNVOprice target cutmarket valuation
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Oral GLP-1 Drug Could Reshape Weight Loss Market as Novo Nordisk Faces Competition

Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.
LLYNVOpharmaceutical competitionweight-loss drug
BenzingaBenzinga··Namrata Sen

Eli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA Review

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.
LLYNVOFDA approvalpharmaceutical competition